百利天恒披露iza-bren联合免疫一线治疗广泛期小细胞肺癌研究数据

证券日报
Mar 19

  本报讯 (记者蒙婷婷)3月18日晚间,四川百利天恒药业股份有限公司(以下简称“百利天恒”)官方微信公众平台发布消息称,由同济大学附属东方医院周彩存教授牵头的iza-bren(EGFR×HER3双抗ADC)联合斯鲁利单抗用于初治广泛期小细胞肺癌(ES-SCLC)的Ⅱ期临床研究取得积极成果,并成功入选由欧洲肿瘤内科学会(ESMO)与国际肺癌研究协会(IASLC)联合主办的2026年欧洲肺癌大会(ELCC2026)口头报告专场。

  据悉,iza-bren是EGFR×HER3双特异性抗体偶联药物(ADC),上述研究评估了iza-bren联合PD-1抗体斯鲁利单抗在广泛期小细胞肺癌(ES-SCLC)患者中的疗效。本次报告BL-B01D1-204-01研究中初治SCLC患者的安全性和疗效结果。

  临床研究结果显示,ADC+PD-1联合疗法一线治疗ES-SCLC,有望确立新的标准方案。同时,在iza-bren2.5mg/kgD1D8Q3W联合斯鲁利单抗治疗组中,中位无进展生存期(PFS)最长,达8.2个月,1年OS率最高,达85.7%。此外,iza-bren联合斯鲁利单抗治疗,以血液学毒性为主,患者无明显体感,临床管理经验丰富。研究结论表明,iza-bren联合斯鲁利单抗在初治ES-SCLC患者中显示出令人鼓舞的疗效,且安全性可控。

(文章来源:证券日报)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10